Next Article in Journal
The Diagnostic, Therapeutic and Prognostic Relevance of Neutrophil Extracellular Traps in Polytrauma
Previous Article in Journal
Identification of a Novel Acid Sphingomyelinase Activity Associated with Recombinant Human Acid Ceramidase
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Biomolecules
Volume 13
Issue 11
10.3390/biom13111624
biomolecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Preclinical Models of Visceral Sarcomas

by
Alice Costa
1,
Livia Gozzellino
2,
Margherita Nannini
2,3,
Annalisa Astolfi
2,
Maria Abbondanza Pantaleo
2,3,* and
Gianandrea Pasquinelli
2,4
1
IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy
2
Department of Medical and Surgical Sciences (DIMEC), University of Bologna, 40138 Bologna, Italy
3
Division of Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy
4
Division of Pathology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy
*
Author to whom correspondence should be addressed.
Biomolecules 2023, 13(11), 1624; https://doi.org/10.3390/biom13111624
Submission received: 2 October 2023 / Revised: 30 October 2023 / Accepted: 2 November 2023 / Published: 6 November 2023
Browse Figures
Versions Notes

Abstract

Visceral sarcomas are a rare malignant subgroup of soft tissue sarcomas (STSs). STSs, accounting for 1% of all adult tumors, are derived from mesenchymal tissues and exhibit a wide heterogeneity. Their rarity and the high number of histotypes hinder the understanding of tumor development mechanisms and negatively influence clinical outcomes and treatment approaches. Although some STSs (~20%) have identifiable genetic markers, as specific mutations or translocations, most are characterized by complex genomic profiles. Thus, identification of new therapeutic targets and development of personalized therapies are urgent clinical needs. Although cell lines are useful for preclinical investigations, more reliable preclinical models are required to develop and test new potential therapies. Here, we provide an overview of the available in vitro and in vivo models of visceral sarcomas, whose gene signatures are still not well characterized, to highlight current challenges and provide insights for future studies.
Keywords: soft tissue sarcomas; preclinical models; cancer-derived cells; patient-derived xenografts; genome-engineered mouse models soft tissue sarcomas; preclinical models; cancer-derived cells; patient-derived xenografts; genome-engineered mouse models
Graphical Abstract

Share and Cite

MDPI and ACS Style

Costa, A.; Gozzellino, L.; Nannini, M.; Astolfi, A.; Pantaleo, M.A.; Pasquinelli, G. Preclinical Models of Visceral Sarcomas. Biomolecules 2023, 13, 1624. https://doi.org/10.3390/biom13111624

AMA Style

Costa A, Gozzellino L, Nannini M, Astolfi A, Pantaleo MA, Pasquinelli G. Preclinical Models of Visceral Sarcomas. Biomolecules. 2023; 13(11):1624. https://doi.org/10.3390/biom13111624

Chicago/Turabian Style

Costa, Alice, Livia Gozzellino, Margherita Nannini, Annalisa Astolfi, Maria Abbondanza Pantaleo, and Gianandrea Pasquinelli. 2023. "Preclinical Models of Visceral Sarcomas" Biomolecules 13, no. 11: 1624. https://doi.org/10.3390/biom13111624

APA Style

Costa, A., Gozzellino, L., Nannini, M., Astolfi, A., Pantaleo, M. A., & Pasquinelli, G. (2023). Preclinical Models of Visceral Sarcomas. Biomolecules, 13(11), 1624. https://doi.org/10.3390/biom13111624

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop